In a setback for Gilead Sciences (GILD), Ukrainian authorities have rejected a key patent for the Sovaldi hepatitis C treatment, according to patient advocacy groups that challenged the patent filing. The decision means that lower-cost generic versions of the medicine may become available by 2020, or a decade sooner than if the patent had been awarded.

“This is a very important achievement for Ukrainian patients,” says Sergiy Dmitriev of the All-Ukrainian Network of People Living with HIV, which filed the patent challenge. “Thanks to this decision, we expect that the price of medicines may drop three-fold, and for us, this means that three times more patients with hepatitis C will have access to modern drugs.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy